Pages that link to "Q62075797"
Jump to navigation
Jump to search
The following pages link to Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma (Q62075797):
Displaying 8 items.
- Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity (Q35749341) (← links)
- Revisiting the biological roles of PAI2 (SERPINB2) in cancer (Q37189305) (← links)
- The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity. (Q37219827) (← links)
- Radiometallated Peptides Targeting Guanylate Cyclase C and the Urokinase-Type Plasminogen Activator Receptor (Q37783622) (← links)
- Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery. (Q38955588) (← links)
- Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer (Q40076948) (← links)
- SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. (Q41193853) (← links)
- Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies (Q90588154) (← links)